ABM Therapeutics Email Format

Biotechnology ResearchCalifornia, United States2-10 Employees

ABM Therapeutics is a biotechnology company focused on discovering and developing small-molecule therapies aimed at brain cancers, including glioblastoma and brain metastases from melanoma, lung, and breast cancers. The company is building an internal pipeline to support a brain medicine R&D platform, supplemented by collaborations with contract research organizations and other partners. Its lead programs include ABM-1310, a BRAFV600-mutant cancer therapy with brain penetration, and ABM-168, an allosteric MEK inhibitor intended to be used in combination with other oncogenic drivers.

Based in San Diego, California, ABM Therapeutics was founded in 2015 by veterans of the biotech and pharmaceutical industries who have extensive experience in neurological drug development. The company has advanced its programs through IND clearances in the United States for ABM-1310 in 2019 and in China in 2021, and an FDA IND for ABM-168 in 2022. Its focus is on patients with brain tumors and brain metastases, addressing areas where current therapies often struggle with brain delivery and treatment resistance.

Sign up for free to view info

Company overview Employee directory